hn clinic trial clinic trial concern hn vaccin intend provid immun influenza virus subtyp hn intend discov pharmacolog effect identifi advers reaction vaccin may achiev human candid vaccin develop unit state unit kingdom protect strain isol human hong kong februari strain die make vaccin littl use april make hn prototyp seed strain avail manufactur august chang prototyp strain offer three new prototyp strain repres three six subclad clade virus respons mani human case occur sinc nation institut allergi infecti diseas niaid award hn vaccin contract aventi pasteur sanofi pasteur swiftwat pennsylvania chiron corpor emeryvill california manufactur use establish techniqu virus grow egg inactiv far purifi formul vaccin univers influenza vaccin could provid protect type influenza would elimin need develop individu vaccin specif virus type vaccin would need reengineer year could protect emerg pandem strain develop univers vaccin requir research identifi conserv region influenza virus exhibit antigen variabl strain time univers vaccin acamflua develop british compani acambi research well acambi meanwhil also acquir sanofi pasteur announc earli august success result anim test vaccin focus viral protein chang rather surfac hemagglutinin neuraminidas protein target tradit flu vaccin univers vaccin make bacteri ferment technolog would great speed rate product possibl cultur chicken egg plus vaccin could produc constant sinc formul would chang still vaccin year away full test approv use juli phase clinic trial human underway vaccin focus viral protein administ small group healthi peopl order verifi safeti product provid initi insight vaccin effect human immun system see also univers flu vaccin current develop state acamflua unclear june nation institut health nih begin enrol particip phase hn studi intranas influenza vaccin candid base medimmun live attenu vaccin technolog oct inovio start phase clinic trial hn vaccin vgxx oct novavax inc pandem influenza vaccin phase trial meet primari object april fda approv influenza virus vaccin hn manufactur sanofi pasteur inc manufactur swiftwat pa facil march hungarian prime minist ferenc gyurcsni report omninvest develop vaccin protect human hn influenza strain vaccin approv countri nation pharmaceut institut commerci product earli result hn clinic trial show poor immunogen compar mcg dose induc immun season flu vaccin trial use two mcg dose produc unaccept result trial use two dose mcg achiev accept level protect current flu vaccin manufactur plant produc enough pandem flu vaccin high dose level adjuvant vaccin appear hold great promis solv grave supplydemand imbal pandem influenza vaccin develop come obstaclesimmunolog regulatori commercialbut also generat excit type vaccin thus far august scientist work glaxosmithklin formula publish trial twodos regimen inactiv splitvirus vaccin adjuvant proprietari oilinwat emuls second inject even low dose mcg exceed eu criterion immun respons see bibliographi lerouxroel septemb sanofi pasteur report press releas inactiv vaccin adjuvant compani proprietari formula induc euaccept level protect two dose mcg glaxosmithklineback team describ accept immun respons two adjuvant microgram mcg dose find three fourth subject protect clade vietnam virus vaccin base drift clade virus indonesia well achiev prepandem vaccin research would ascertain right dose dose interv determin long prime last solv puzzl measur prime immun regulatori author would determin trial design could deliv answer public discuss would necessari prepandem vaccin accept safeti datum would need gather vaccin go use studi complet januari purpos studi determin whether receiv vaccin past prime immun system respond rapid anoth dose vaccin subject particip studi particip previous vaccin studi involv ahongkong virus fall univers rochest studi start april studi complet februari purpos studi determin doserel safeti flu vaccin healthi adult determin doserel effect flu vaccin healthi adult approxim month follow receipt dose vaccin provid inform select good dose level studi studi start octob studi complet june purpos studi determin whether third dose vaccin contain avietnam provid immun two dose subject particip studi particip dmid protocol involv avietnam studi subject ask receiv third dose vaccin level administ protocol studi start octob studi complet august studi intend examin safeti doserel immunogen three dosag level influenza ahn vaccin compar salin placebo give intramuscular healthi elder adult approxim week apart studi start march expect complet novemb random control doubleblind doserang phase iii studi healthi adult year old design investig safeti reactogen doserel immunogen investig inactiv influenza ahn virus vaccin give alon combin aluminum hydroxid secondari goal guid select vaccin dosag level expand phase ii trial base reactogen immunogen profil dose optim appli young old subject popul subsequ studi subject meet entri criterion studi enrol one studi site random group receiv two dose influenza ahn vaccin contain mcg ha without aluminum hydroxid adjuv inject vaccin dose group studi start march studi complet novemb studi design gather critic inform safeti toler immunogen capabl induc immun respons ahn virus vaccin healthi adult healthi adult age particip studi subject particip month random place one sever differ studi group receiv differ dose vaccin vaccin plus adjuv placebo subject receiv two inject assign studi product day apart muscl tissu subject keep journal temperatur advers effect studi visit small amount blood also draw first inject day inject month second inject studi start octob studi complet januari australian studi test safeti immunogen hn pandem influenza vaccin healthi adult studi start januari studi complet februari random doubleblind placebocontroll stage doserang phase iii studi evalu safeti reactogen immunogen dose inactiv influenza ahn vaccin healthi child age year studi design investig safeti toler doserel immunogen investig inactiv influenza ahn vaccin secondari goal identifi optim dosag level vaccin generat accept immunogen respons maintain adequ safeti profil